FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreACR emphasized the importance of bringing cancer screening directly to the communities that need it most to ensure early detection and intervention.
ACR® joined multiple medical organizations in expressing support for the Mobile Cancer Screening Act (H.R. 4417). The bipartisan bill, introduced in July by cosponsors U.S. Reps. Raul Ruiz, MD (D-CA), Gabe Evans (R-CO) and Debbie Wasserman Schultz (D-FL), would significantly enhance access to cancer screening services for underserved and rural communities across the United States.
The organizations emphasized to cosponsors the importance of bringing cancer screening directly to the communities that need it most to ensure early detection and intervention, regardless of geographic location or socioeconomic status. They told lawmakers they will work them to advance the bill through Congress.
ACR and the medical community look forward to working with Congress to advance this legislation. For more information or if you have questions, contact Ashley Walton, ACR Government Affairs Director.
FDA Highlights Programs for Innovators at ACR DSI Summit
The FDA joined the ACR®️ Data Science Summit June 9 to give an update about its Total Product Life Cycle Advisory Program.
Read moreLower Fee Now in Effect to File No Surprises Act Disputes
Federal agencies released a final rule that updates the No Surprises Act independent dispute resolution process. The rule lowers the IDR administrative or filing fee from $115 to $15.
Read moreACR Urges Funding for NIH All of Us Program
ACR urges Congress to provide dedicated funding for NIH’s All of Us Research Program, a leader in precision medicine technologies and a valuable tool for researchers.
Read more